Interstitial cystitis/bladder pain syndrome, recurrent urinary tract infections and other forms of cystitis signifi-cantly impact the quality of life of patients with chronic bladder disorders and impose a considerable economic burden on health systems. Effective management is essential to provide symptom relief and to reduce the negative impact of chronic bladder disorders. Identifying the appropriate pharmacological or non-pharmacological approach is essential, and there is a growing evidence base for the use of intravesical hyaluronic acid and chon-droitin sulfate in several bladder conditions, including recurrent urinary tract infections.
EngelerDS, BaranowskiAP, BorovickaJ, . EAU guidelines on chronic pelvic pain. Presented at the EAU Annual Congress London 2017. ISBN 978-90-79754-91-5. Publisher: EAU Guidelines Office, Arnhem, The Netherlands. https://uroweb.org/guideline/chronic-pelvic-pain. Accessed July 22, 2017.
2.
BerrySH, ElliottMN, SuttorpM, . Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult fe-males in the United States. J Urol. 2011;186(2):540-544.
3.
SuskindAM, BerrySH, SuttorpMJ, ElliottMN, ClemensJQ. Symptom persistence in a community cohort of women with interstitial cystitis/bladder pain syndrome (IC/BPS): 3-, 6-, 9-, and 12-month follow-up from the RICE cohort. Int Urogynecol J.2014;25(12):1639-1643.
4.
KriegerJN, StephensAJ, LandisJR, . Relationship between chronic nonurological associated somatic syndromes and symptom severity in urological chronic pelvic pain syndromes: baseline evaluation of the MAPP study. J Urol.2015;193(4): 1254-1262.
5.
HepnerKA, WatkinsKE, ElliottMN, ClemensJQ, HiltonLG, BerrySH. Suicidal ideation among patients with bladder pain syndrome/interstitial cystitis. Urology. 2012;80(2):280-285.
6.
ChenHM, LinCC, KangCS, LeeCT, LinHC, ChungSD. Bladder pain syndrome/interstitial cystitis increase the risk of coronary heart disease. Neurourol Urodyn. 2014;33(5):511-515.
7.
TroxelWM, BoothM, BuysseDJ, . Sleep disturbances and nocturnal symptoms: relationships with quality of life in a population-based sample of women with interstitial cystitis/bladder pain syndrome. J Clin Sleep Med.2014;10(12):1331-1337.
8.
NickelJC, TrippD, TealV, . Sexual function is a determinant of poor quality of life for women with treatment refractory interstitial cystitis. J Urol.2007;177(5):1832-1836.
9.
BogartLM, SuttorpMJ, ElliottMN, ClemensJQ, BerrySH. Prevalence and correlates of sexual dysfunction among women with bladder pain syndrome/interstitial cystitis. Urology. 2011;77(3):576-580.
10.
GardellaB, PorruD, NappiRE, DaccoMD, ChiesaA, SpinilloA.Interstitial cystitis is associated with vulvodynia and sexual dys-function-a case-control study. J Sex Med.2011;8(6):1726-1734.
11.
ClemensJQ, MeenanRT, RosettiMC, KimesT, CalhounEA. Costs of interstitial cystitis in a managed care population. Urology. 2008;71(5):776-780.
RiedlC, EngelhardtP, SchwarzB.Treatment costs of bladder pain syndrome/interstitial cystitis in Austria: a pharmacoeco-nomic approach following current guidelines. Clin Drug Inves-tig.2013;33(10):737-742.
14.
ClemensJQ, MarkossianT, CalhounEA. Comparison of economic impact of chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis/painful bladder syndrome. Urology. 2009;73(4):743-746.
15.
BeckettMK, ElliottMN, ClemensJQ, EwingB, BerrySH. Con-sequences of interstitial cystitis/bladder pain symptoms on women's work participation and income: results from a national household sample. J Urol.2014;191(1):83-88.
16.
PayneCK, JoyceGF, WiseM, ClemensJQ, Urologic Diseases in America P. Interstitial cystitis and painful bladder syndrome. J Urol.2007;177(6):2042-2049.
17.
SmitSG, HeynsCF. Management of radiation cystitis. Nat Rev Urol.2010;7(4):206-214.
18.
Rapariz-GonzálezM, Castro-DiazD, Mejia-RendonD.Eurcis Evaluation of the impact of the urinary symptoms on quality of life of patients with painful bladder syndrome/chronic pelvic pain and radiation cystitis: EURCIS study. Actas Urol Esp.2014;38(4):224-231.
19.
OscarssonN, ArnellP, LoddingP, RickstenSE, Seeman-LoddingH.Hyperbaric oxygen treatment in radiation-induced cystitis and proctitis: a prospective cohort study on patient-perceived quality of recovery. Int J Radiat Oncol Biol Phys.2013;87(4):670-675.
20.
SommarivaM, LazzeriM, AbrateA, GuazzoniG, SandriS, Mon-torsiF.Intravesical hyaluronic acid and chondroitin sulphate improve symptoms and quality of life in patients with late radiation tissue cystitis: An investigative pilot study. Eur J Inflamm. 2014;12(1):177-185.
21.
SmartD, WallingtonM.A cost-analysis case study of radiation cystitis treatment including hyperbaric oxygen therapy. Diving Hyperb Med.2012;42(2):92-97.
22.
GrieblingTL. Urologic diseases in America project: trends in resource use for urinary tract infections in women. J Urol.2005;173(4):1281-1287.
RenardJ, BallarmiS, MascarenhasT, . Recurrent lower urinary tract infections have a detrimental effect on patient quality of life: A prospective, observational study. Infect Dis Ther.2014.
25.
CicioneA, CantielloF, UccieroG, . Intravesical treatment with highly-concentrated hyaluronic acid and chondroitin sulphate in patients with recurrent urinary tract infections: Results from a multicentre survey. Can Urol Assoc J.2014;8 (9-10):E721-727.
26.
DamianoR, QuartoG, Baval, . Prevention of recurrent urinary tract infections by intravesical administration of hy-aluronic acid and chondroitin sulphate: a placebo-controlled randomised trial. Eur Urol.2011;59(4):645-651.
27.
CianiO, GrassiD, TarriconeR.An economic perspective on urinary tract infection: the “costs of resignation”. Clin Drug Invest.2013;33(4):255-261.
28.
EellsSJ, BharadwaK, McKinnellJA, MillerLG. Recurrent urinary tract infections among women: comparative effectiveness of 5 prevention and management strategies using a Markov chain Monte Carlo model. Clin Infect Dis.2014;58(2):147-160.
29.
CooperMA, ShlaesD.Fix the antibiotics pipeline. Nature. 2011;472(7341):32.
30.
SanchezGV, BabikerA, MasterRN, LuuT, MathurA, BordonJ.Antibiotic resistance among urinary isolates from female outpatients in the United States in 2003 and 2012. Antimi-crob Agents Chemother. 2016;60(5):2680-2683.
31.
OteoJ, BautistaV, LaraN, . Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli. J Antimicrob Chemother. 2010;65(11):2459-2463.
